Analyst Price Targets — RMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 31, 2026 10:34 am | — | KeyBanc | $267.00 | $240.33 | TheFly | ResMed price target raised to $267 from $255 at KeyBanc |
| August 19, 2026 8:39 am | — | Redburn Partners | $230.00 | $219.98 | TheFly | ResMed initiated with a Neutral at Rothschild & Co Redburn |
| August 7, 2026 11:59 am | — | Robert W. Baird | $213.00 | $212.39 | TheFly | ResMed price target lowered to $213 from $217 at Baird |
| August 7, 2026 10:27 am | — | KeyBanc | $255.00 | $223.24 | TheFly | ResMed price target lowered to $255 from $260 at KeyBanc |
| July 21, 2026 12:57 pm | David Low | UBS | $300.00 | $195.97 | StreetInsider | ResMed (RMD) PT Lowered to $300 at UBS |
| July 16, 2026 10:26 am | — | RBC Capital | $234.00 | $198.57 | TheFly | ResMed downgraded to Sector Perform from Outperform at RBC Capital |
| July 15, 2026 11:26 am | — | Mizuho Securities | $220.00 | $193.01 | TheFly | ResMed price target lowered to $220 from $235 at Mizuho |
| July 10, 2026 1:06 pm | — | Jefferies | $225.00 | $204.50 | TheFly | ResMed price target lowered to $225 from $240 at Jefferies |
| July 8, 2026 11:43 am | — | RBC Capital | $276.00 | $219.75 | TheFly | ResMed price target lowered to $276 from $321 at RBC Capital |
| July 8, 2026 10:21 am | — | Wells Fargo | $225.00 | $219.75 | TheFly | ResMed price target lowered to $225 from $227 at Wells Fargo |
Latest News for RMD
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD).
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. (“ResMed” or the “Company”) (NYSE: RMD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Canada Pension Plan Investment Board bought a new stake in shares of ResMed Inc. (NYSE: RMD) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 55,511 shares of the medical equipment provider's stock, valued at approximately $10,818,000.
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 24th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026. Resmed's webcast presentation will begin at approximately 10:00 a.m. (Eastern Time).
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.